Rituximab tops other disease-modifying tx options in MS

January 9, 2018

(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published online Jan. 8 in JAMA Neurology.

Mathias Granqvist, M.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a using prospectively collected data for patients in Sweden with newly diagnosed RRMS. The effectiveness and drug discontinuation rates of rituximab were compared with those of injectable DMTs, , fingolimod, and natalizumab.

Of the 494 patients, 43.5 percent received an injectable DMT, 17.4 percent dimethyl fumarate, 3.4 percent fingolimod, 10.1 percent natalizumab, 24.3 percent rituximab, and 1.2 percent other DMT. The researchers found that there were pronounced regional preferences, with 81 and 18 percent of patients in Västerbotten and Stockholm, respectively, receiving rituximab. The annual discontinuation rates were 0.03, 0.53, 0.32, 0.38, and 0.29 for rituximab, injectable DMTs, dimethyl fumarate, fingolimod, and natalizumab, respectively. The main reason for discontinuation of injectable DMTs, dimethyl fumarate, and fingolimod was continued disease activity; the main reason for discontinuation of natalizumab was positive John Cunningham virus serology results. Compared with injectable DMTs and dimethyl fumarate, the rates of clinical relapse and/or neuroradiologic disease activity were significantly lower for rituximab, with a tendency for lower relapse rates relative to and .

"Collectively, our findings suggest that rituximab performs better than other commonly used DMTs in patients with newly diagnosed RRMS," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Biogen, which manufactures .

Explore further: Rituximab effective for lupus-associated cytopenia

More information: Abstract/Full Text

Related Stories

Rituximab effective for lupus-associated cytopenia

December 27, 2017
(HealthDay)—Rituximab treatment seems effective for systemic lupus erythematosus (SLE)-associated immune cytopenias, with an overall initial response rate of 86 percent, according to a study published online Dec. 16 in ...

PFS up with obinutuzumab-based Tx in follicular lymphoma

October 5, 2017
(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...

Natalizumab shows promise for teens with multiple sclerosis

February 22, 2013
(HealthDay)—Natalizumab may be safe in pediatric multiple sclerosis (MS) patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.

Adding rituximab to chemo ups event-free survival in ALL

September 20, 2016
(HealthDay)—For young adults with acute lymphoblastic leukemia (ALL), adding rituximab to chemotherapy is associated with increased event-free survival, according to a study published in the Sept. 15 issue of the New England ...

Dimethyl fumarate linked to development of PML

April 9, 2015
(HealthDay)—An active ingredient in some psoriasis and multiple sclerosis medications, dimethyl fumarate, has been linked to two cases of progressive multifocal leukoencephalopathy (PML), according to two letters published ...

Tocilizumab treats rheumatoid arthritis after non-TNFi failure

March 30, 2016
(HealthDay)—For patients with rheumatoid arthritis (RA) and a first non-tumor necrosis factor inhibitor (TNFi) failure, treatment with tocilizumab seems more efficacious than abatacept or rituximab, according to a study ...

Recommended for you

iReadMore app improves reading ability of stroke patients

June 18, 2018
A new smart app designed to improve the reading ability of people who have suffered a stroke provides 'significant' improvements, a UCL study has found.

Silence is golden when it comes to how our brains work

June 18, 2018
It's the comparative silence between the firing spikes of neurons that tells what they are really up to, scientists report.

Observing brain plasticity during cello training

June 15, 2018
Music acquisition provides an excellent model of neural plasticity, and has become a hot research subject in neurology. Music performance provides an unmatched array of neural complexities revealing how neural networks are ...

New discovery about the brain's water system may prove beneficial in stroke

June 15, 2018
Water is transported from the blood into the brain via an ion transporter, according to a new study on mice conducted at the University of Copenhagen. If the mechanism can be targeted with medicine, it may prove relevant ...

Study shows how intensive instruction changes brain circuitry in struggling readers

June 14, 2018
The early years are when the brain develops the most, forming neural connections that pave the way for how a child—and the eventual adult—will express feelings, embark on a task, and learn new skills and concepts.

When emotional memories intrude, focusing on context could help, study finds

June 14, 2018
When negative memories intrude, focusing on the contextual details of the incident rather than the emotional fallout could help minimize cognitive disruption and redirect the brain's resources to the task at hand, suggests ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.